We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study.
- Authors
Johannes F. E. Mann; Patrick Sheridan; Matthew J. McQueen; Claes Held; J. Malcolm O. Arnold; George Fodor; Salim Yusuf; Eva M. Lonn; on behalf of the HOPE-2 investigators
- Abstract
Background. Elevated plasma homocysteine levels are reported to be associated with higher rates of vascular diseases. Plasma homocysteine increases in chronic kidney disease (CKD) and could contribute to the increased cardiovascular risk in CKD. Methods. Participants aged 55 years or older with CKD, defined as estimated GFRn = 307) or placebo (n = 312) daily for 5 years. The primary outcome was a composite of death from cardiovascular causes, myocardial infarction and stroke. Results. Mean baseline plasma homocysteine was 15.9 ± 7.3 μmol/l in the active treatment group and 15.7 ± 5.7 µmol/l in placebo group and decreased to 11.9 ± 3.3 µmol/l (P P = 0.25). There were no significant treatment benefits on death from cardiovascular causes (1.24; 0.84–1.83), myocardial infarction (1.10; 0.76–1.61) and stroke (1.00; 0.54–1.85). More participants in the active treatment group were hospitalized for heart failure (1.98; 1.21–3.26; P = 0.007) and for unstable angina (1.70; 1.02–2.83; P = 0.04). Incidence of primary outcome increased with decreasing GFR. Conclusions. Active treatment with B vitamins lowered homocysteine levels in participants with CKD but did not reduce cardiovascular risk.
- Subjects
HEART diseases; THERAPEUTICS; DISEASE complications; KIDNEY diseases; PLACEBOS
- Publication
Nephrology Dialysis Transplantation, 2008, Vol 23, Issue 2, p645
- ISSN
0931-0509
- Publication type
Article